| 发明名称 | Methods of treating and preventing inflammatory bowel disease involving IL-13 and NKT cells | ||
| 摘要 | The present invention provides a method of treating or preventing the inflammatory response of ulcerative colitis or Crohn's disease in a subject comprising administering to the subject an effective amount of a substance that inhibits the binding of IL-13 to IL-13 receptors on NKT cells or delivers an effector molecule to the NKT cells. | ||
| 申请公布号 | US9072716(B2) | 申请公布日期 | 2015.07.07 |
| 申请号 | US200611918711 | 申请日期 | 2006.04.14 |
| 申请人 | The United States of America, as represented by the Secretary Department of Health by Human Servies | 发明人 | Strober Warren;Fuss Ivan;Mannon Peter;Preiss Jan;Puri Raj;Kawakami Koji;Fichtner-Feigl Stefan;Kitani Atsushi |
| 分类号 | A61K51/08;A61K38/20;A61K31/00;A61K38/16;C07K14/54 | 主分类号 | A61K51/08 |
| 代理机构 | Locke Lord LLP | 代理人 | Locke Lord LLP ;Zerhusen Bryan D.;McCool Gabriel J. |
| 主权项 | 1. A method of treating Crohn's disease (CD) or ulcerative colitis (UC) in inflammatory bowel disease in a subject comprising administering to the subject an effective amount of a substance that inhibits the binding of IL-13 to IL-13 receptors on NKT cells, wherein the substance comprises a modified IL-13, wherein the modified IL-13 comprises a mutation consisting of substituting a glutamic acid residue at position 13 of native human IL-13 (hIL-13) with a neutrally charged or positively charged amino acid residue, and wherein the modified IL-13 is linked to an effector molecule, wherein the effector molecule comprises a cytotoxin or radionuclide. | ||
| 地址 | Washington DC US | ||